Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results - Ipsen

About this study

Understanding differences in treatment outcomes is important for improving cancer care. It helps healthcare staff and systems choose the best treatments for each patient, improving survival rates and the patients’ quality of life. It also highlights gaps in access to care, helps update medical guidelines, and ensures resources are used effectively. This study uncovered insights from 281 patients receiving treatment for renal cell carcinoma, an advanced kidney cancer, in the UK. 

The study utilised real-world data from hospital and prescription records of patients, aged 18 or over, with advanced kidney cancer treated in cancer centres across the UK. These records spanned from April 2015 to June 2022. Access to patient level data was vital as it provided detailed information about different treatment sequences, durations, and outcomes for patients. All data was anonymised and documents relating to the study were redacted to protect patient privacy.

By conducting the study in a secure and anonymised way, Ipsen were able to ensure that only relevant information relating to patients’ care was included. 

This study focussed on how well different treatments work for advanced kidney cancer for patients who have already had a first round of therapies and looked specifically at the drug cabozantinib.  Patients who received cabozantinib stayed on it longer than those on other treatments approved for this type of kidney cancer. Overall, patients who took cabozantinib lived for an average of 15 months after starting it, with the results suggesting cabozantinib is an effective treatment option after initial combination therapies.